2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. Sodium Channel

Sodium Channel

Na channels; Na+ channels

Sodium Channel

Related Products

PDF 3.33 MB

Sodium channels are integral membrane proteins that form ion channels, conducting sodium ions (Na+) through a cell's plasma membrane. They are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). In excitable cells such as neurons, myocytes, and certain types of glia, sodium channels are responsible for the rising phase of action potentials. Voltage-gated Na+ channels can exist in any of three distinct states: deactivated (closed), activated (open), or inactivated (closed). Ligand-gated sodium channels are activated by binding of a ligand instead of a change in membrane potential.

Sodium Channel Isoform Specific Products:

Sodium Channel Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-W011240
    Hydroflumethiazide
    		Inhibitor 99.38%
    Hydroflumethiazide (Methforylthiazidine) is an orally active and potent thiazide diuretic. Hydroflumethiazide possesses the ability to directly stimulate A cell secretion in the normal and alloxan diabetic pancreas.
    Hydroflumethiazide
  • HY-B1007
    Butacaine
    		99.84%
    Butacaine is a reversible nerve conduction blocker. Butacaine acts on the nervous system and nerve fibers, can cause both sensory and motor paralysis. Butacaine inhibits the NavBh currents. Butacaine can form inclusion complexes with α-cyclodextrin (α-CD) and β-cyclodextrin (β-CD). Butacaine is commonly used as a negative control for other local anesthetics.
    Butacaine
  • HY-B1430
    Butamben
    		Inhibitor 99.82%
    Butamben (Butyl 4-aminobenzoate) results in long-lasting relief from pain, without impairing motor function or other sensory functions.
    Butamben
  • HY-157786
    XPC-5462
    		Inhibitor 98.25%
    XPC-5462 is a NaV1.6 and NaV1.2 inhibitor with the IC50s of 10.9 nM and 10.3 nM, respectively. XPC-5462 suppresses epileptiform activity in an ex vivo brain slice seizure model.
    XPC-5462
  • HY-B1642
    Ethotoin
    		Inhibitor 99.61%
    Ethotoin (Peganone) is an orally active anticonvulsant agent used in epilepsy research, Ethotoin is a hydantoin, similar to phenytoin.
    Ethotoin
  • HY-12796A
    Raxatrigine hydrochloride
    		Inhibitor 99.10%
    Raxatrigine hydrochloride (GSK-1014802 hydrochloride) is a novel small molecule state-dependent sodium channel blocker; Nav1.7 sodium channel inhibitor.
    Raxatrigine hydrochloride
  • HY-119980
    Fluphenazine
    		Inhibitor 98.70%
    Fluphenazine is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine blocks neuronal voltage-gated sodium channels. Fluphenazine acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2.
    Fluphenazine
  • HY-131182
    DS-1971a
    		Inhibitor 99.61%
    DS-1971a is a potent, selective, and orally active NaV1.7 inhibitor, with IC50s of 22.8 and 59.4 nM for hNaV1.7 and mNaV1.7, respectively. DS-1971a exerts analgesic effects.
    DS-1971a
  • HY-100727
    AM-2099
    		Inhibitor 98.37%
    AM-2099 is a potent and selective inhibitor of voltage-gated sodium channel Nav1.7 with an IC50 of 0.16 μM for human Nav1.7.
    AM-2099
  • HY-131879
    NS383
    		99.83%
    NS383 is a potent and uniquely selective inhibitor of rat ASICs containing 1a and/or 3 subunits. NS383 inhibits H(+)-activated currents recorded from rat homomeric ASIC1a, ASIC3, and heteromeric ASIC1a+3 with IC50 values ranging from 0.61 to 2.2 μM. NS383 is well tolerated and capable of reversing pathological painlike behaviors, presumably via peripheral actions, but possibly also via actions within central pain circuits.
    NS383
  • HY-108464A
    Phenamil methanesulfonate
    		Inhibitor 98.1%
    Phenamil methanesulfonate, an analog of Amiloride (HY-B0285), is a more potent and less reversible epithelial sodium channel (ENaC) blocker with an IC50 of 400 nM. Phenamil methanesulfonate is also a competive inhibitor of TRPP3 and inhibits TRPP3-mediated Ca2+ transport with an IC50 of 140 nM in a Ca2+ uptake assay. Phenamil methanesulfonate is an intriguing small molecule to promote bone repair by strongly activating BMP signaling pathway. Phenamil methanesulfonate is used for the research of cystic fibrosis lung disease.
    Phenamil methanesulfonate
  • HY-B1243
    Propoxycaine hydrochloride
    		Inhibitor 99.98%
    Propoxycaine hydrochloride inhibits voltage-gated sodium channels, and thereby inhibits the ionic flux required for the initiation and conduction of impulses. Propoxycaine hydrochloride application can lead to a loss of sensation.
    Propoxycaine hydrochloride
  • HY-14948
    Carisbamate
    		98.75%
    Carisbamate (RWJ-333369) is an orally active neuromodulator. Carisbamate prevents the development and production of epilep-like discharges and has a neuroprotective effect after in vitro epilepticus-like injury. Carisbamate has good antiepileptic activity in genetic models of generalized and nonconvulsive epilepsy.
    Carisbamate
  • HY-160903
    Suzetrigine phenol
    		99.39%
    Suzetrigine phenol is the phenolate form of the sodium channel modulator Suzetrigine (HY-148800). Suzetrigine (VX-548) is an orally active and highly selective inhibitor of NaV1.8.
    Suzetrigine phenol
  • HY-16723
    Funapide
    		Inhibitor 99.83%
    Funapide (TV 45070; XEN402) is an orally active inhibitor of voltage-gated sodium channels (VGSC) in the peripheral nervous system with IC50 values ??of 84 nM and 54 nM for Nav1.5 and Nav1.7, respectively. Funapide has analgesic effects.
    Funapide
  • HY-116448
    Metaflumizone
    		Inhibitor
    Metaflumizone is a semicarbazone insecticide, acts as a potent sodium channel blocker.
    Metaflumizone
  • HY-110325
    PF-04885614
    		Inhibitor
    PF-04885614 is a potent NaV1.8 inhibitor, extracted from patent US2018328915. PF-04885614 has potential for neurological and neurodevelopmental diseases treatment.
    PF-04885614
  • HY-155635
    Nav1.8-IN-4
    		Inhibitor 99.78%
    Nav1.8-IN-4 (compound 9a) is a Nav1.8 channel inhibitor (IC50=0.014 μM). Nav1.8-IN-4 can be used for research on pain-related diseases.
    Nav1.8-IN-4
  • HY-B1386
    Halazone
    		Activator
    Halazone is an atypical antimicrobial sulfonamide derivative and a carbonic anhydrase II inhibitor with a Kd value of 1.45 µM. Halazone protects sodium channels from inactivation. Halazone is widely used for disinfection of drinking water.
    Halazone
  • HY-108506
    Licarbazepine
    		Inhibitor 99.77%
    Licarbazepine (BIA 2-005; GP 47779) is a voltage-gated sodium channel blocker with anticonvulsant and mood-stabilizing effects.
    Licarbazepine
Cat. No. Product Name / Synonyms Application Reactivity
Sodium Channel Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.